Table 4.
Kendall's Tau Rank Correlations: Change in Mean Diffusivity Values Following 6 Months of Medical Cannabis Use Versus Medical Cannabis Characteristics (Two-Tailed)
| |
MC use characteristics: 6 months |
|||
|---|---|---|---|---|
| |
MC uses/week (n=21)a |
THC mg/week (n=15)b |
CBD mg/week (n=15)b |
Urinary THC/Cr (ng/mg) (n=12)c |
| rτ (p) | rτ (p) | rτ (p) | rτ (p) | |
| Mean diffusivity difference scores (baseline – 6 months) | ||||
| Left genu | 0.169 (0.289) | −0.038 (0.843) | 0.695 (<0.001) | 0.152 (0.493) |
| Right genu | 0.087 (0.586) | −0.153 (0.428) | 0.543 (0.005) | <0.001 (>0.999) |
| Left corona radiata | 0.184 (0.250) | −0.144 (0.457) | 0.478 (0.013) | −0.046 (0.837) |
| Right corona radiata | 0.169 (0.289) | −0.057 (0.766) | 0.562 (0.004) | −0.015 (0.945) |
| Left external capsule | 0.183 (0.250) | 0.019 (0.921) | 0.486 (0.012) | 0.030 (0.891) |
| Right external capsule | 0.188 (0.238) | 0.029 (0.882) | 0.555 (0.004) | <0.001 (>0.999) |
| Left anterior limb | 0.183 (0.250) | −0.038 (0.843) | 0.429 (0.026) | 0.061 (0.784) |
| Right anterior limb | 0.202 (0.204) | 0.019 (0.921) | 0.448 (0.020) | 0.030 (0.891) |
Twenty-two MC patients completed a 6-month follow-up visit, but one patient was identified as an outlier (>3×outside the IQR) and removed from the MC uses/week analyses.
Fifteen MC patients had constituent information on MC products at the 6-month follow-up.
Fourteen MC patients tested positive for THC at their 6-month follow-up visit and had their samples sent out for urinary THC/Cr quantification, but two patients were identified as outliers (>3×outside the IQR) and removed from these analyses.
Bold numbers are significant at Bonferroni-corrected p≤0.025. Italicized numbers are findings that did not survive Bonferroni correction p≤0.050.
CBD, cannabidiol; Cr, creatinine; THC, delta-9-tetrahydrocannabinol.